ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2094

Prevalence of Organ Involvement in Mixed Connective Tissue Disease

Javier Narváez1, Maria Pascual2, Gloria Albert Espi3, Milena Millan4, Mercè López de Recalde5, Juan José Alegre6, Ivan Castellví7, Carmen Gomez Vaquero5 and Joan Miquel Nolla8, 1Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain, 2Rheumatology, Hospital Universitari de Bellvitge, Barcelona, Spain, 3Rheumatology Department, Hospital Universitario Doctor Peset, Valencia, Spain, 4Rheumatology, Hospital de Sant Pau, Barcelona, Spain, 5Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, 6Sección de Reumatología Hospital Universitario Dr Peset Valencia, Valencia, Spain, 7Rheumatology, Hospital Universitari de la Santa Creu i Sant Pau, Barcelona, Spain, 8Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Mixed connective tissue disease (MCTD)

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose:  : Mixed connective tissue disease (MCTD) is characterized by overlapping features of SLE, SSc, PM/DM and rheumatoid arthritis together with the presence of high-titre of anti-RNP antibodies. Its most common clinical manifestations are Raynaud’s phenomenon, arthritis, sclerodactyly, edema in the hands and myositis. However, organ involvement is more extensive than first descriptions reported. The disease can be serious with development of pulmonary, kidney, cardiovascular, gastrointestinal and neurological manifestations. The objective of the present study was to evaluate the frequency and the different types of organ damage in a well characterized cohort of patients with MCTD.

Methods: Ambispective study of 42 MTCD patients, all of them fulfilling the diagnostic criteria proposed by Alarcon-Segovia (J Rheumatol 1989;16:328-34), with a minimal follow-up after the first clinical presentation of at least 2 yr. The endpoint of patient follow-up was the date of the last clinic visit.

Results: At the end of the follow-up period (median ± SD: 117.3 ± 63.1 months; minimum, maximum: 28-432 months), 69% of patients (29/42) had 1 or more organ involvement.

Esophageal dysmotility and reflux disease was the most prevalent complication, being observed in 43% (18/42) of cases. Pulmonary abnormalities were also common, being found in 38% of patients (16/42). The most frequent lung manifestations were diffuse interstitial lung disease in 24% (10/42) of patients (including 6 cases of nonspecific interstitial pneumonitis, 3 cases of usual interstitial pneumonitis and 1 case of lymphocytic interstitial pneumonia), and pleuritis in 19% (8/42). Other pulmonary complications include primary pulmonary hipertension in 12% of patients (5/42) and shrinking lung syndrome in 2% (1/42).

Neurological disease was observed in 19% (8/42) of patients (including 4 cases of trigeminal neuropathy, 1 with dyskinesias, 1 with sensory peripheral neuropathy, 1 case of intracraneal haemorrhage, and 1 with CNS vasculitis), cardiac involvement in 12% (5/42) (4 cases of pericarditis which was usually mild, and 1 case of myocarditis), and renal involvement in 10% (4/42), (2 mesangial glomerulonephritis [GN], 1 focal proliferative GN, and 1 diffuse proliferative GN).

Conclusion:  MCTD is a well-defined entity with a wide spectrum of clinical manifestations. Long-term follow-up reveal that some patients may have mild self-limited disease, whereas others may develop severe major organ involvement which does not always have a good prognosis


Disclosure: J. Narváez, None; M. Pascual, None; G. Albert Espi, None; M. Millan, None; M. López de Recalde, None; J. J. Alegre, None; I. Castellví, None; C. Gomez Vaquero, None; J. M. Nolla, None.

To cite this abstract in AMA style:

Narváez J, Pascual M, Albert Espi G, Millan M, López de Recalde M, Alegre JJ, Castellví I, Gomez Vaquero C, Nolla JM. Prevalence of Organ Involvement in Mixed Connective Tissue Disease [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/prevalence-of-organ-involvement-in-mixed-connective-tissue-disease/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-of-organ-involvement-in-mixed-connective-tissue-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology